In a retrospective study of 190 NSCLC patients with BoM, combining denosumab with first‐ or second‐generation EGFR–TKI was associated with improved OS (26.6 vs. 20.1 months; p = 0.015).20 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.